The University of Southampton
University of Southampton Institutional Repository

Patterns of use of pancreatic enzyme supplements in fibrosing colonopathy: Implications for pathogenesis.

Patterns of use of pancreatic enzyme supplements in fibrosing colonopathy: Implications for pathogenesis.
Patterns of use of pancreatic enzyme supplements in fibrosing colonopathy: Implications for pathogenesis.
Sixteen pathologically confirmed and 14 suspected cases of a new disease entity, fibrosing colonopathy, have been described in the UK and the US in children with cystic fibrosis since 1991. The patterns of use of pancreatic enzyme supplements in cases were compared with use in controls and in the market, in the 2 years prior to surgery for fibrosing colonopathy or the equivalent date in controls. The disease was only found in children with cystic fibrosis who had received brands of pancreatic enzyme supplement coated with methacrylic acid copolymer, for a period of at least 6 months. The risk was dose-related. No cases could be identified in children who had only received other pancreatic enzyme formulations, irrespective of the strength of the formulation or the dose.
fibrosing colonopathy, pancreatic enzyme supplements, cystic fibrosis, enteric coating
1053-8569
347-358
Bakowski, Marie T.
5ccf108b-45b1-49cc-8600-765ec86a9c07
Prescott, Philip
6790aa6d-a682-4c63-afcf-62cb64dbf41b
Bakowski, Marie T.
5ccf108b-45b1-49cc-8600-765ec86a9c07
Prescott, Philip
6790aa6d-a682-4c63-afcf-62cb64dbf41b

Bakowski, Marie T. and Prescott, Philip (1997) Patterns of use of pancreatic enzyme supplements in fibrosing colonopathy: Implications for pathogenesis. Pharmacoepidemiology and Drug Safety, 6 (5), 347-358.

Record type: Article

Abstract

Sixteen pathologically confirmed and 14 suspected cases of a new disease entity, fibrosing colonopathy, have been described in the UK and the US in children with cystic fibrosis since 1991. The patterns of use of pancreatic enzyme supplements in cases were compared with use in controls and in the market, in the 2 years prior to surgery for fibrosing colonopathy or the equivalent date in controls. The disease was only found in children with cystic fibrosis who had received brands of pancreatic enzyme supplement coated with methacrylic acid copolymer, for a period of at least 6 months. The risk was dose-related. No cases could be identified in children who had only received other pancreatic enzyme formulations, irrespective of the strength of the formulation or the dose.

This record has no associated files available for download.

More information

Published date: 1997
Keywords: fibrosing colonopathy, pancreatic enzyme supplements, cystic fibrosis, enteric coating
Organisations: Statistics

Identifiers

Local EPrints ID: 29973
URI: http://eprints.soton.ac.uk/id/eprint/29973
ISSN: 1053-8569
PURE UUID: fa68a8c3-de40-4982-b704-fbf3f3606aa4

Catalogue record

Date deposited: 16 Mar 2007
Last modified: 08 Jan 2022 15:53

Export record

Contributors

Author: Marie T. Bakowski
Author: Philip Prescott

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×